Xenon Pharmaceuticals (XENE) had its price target lowered by Wedbush from $64.00 to $63.00. They now have an "outperform" rating on the stock.
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward [Yahoo! Finance]
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge [Yahoo! Finance]
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares